This teaser has gotten a lot of attention from my readers, as do all the pitches thrown by the folks at Stansberry’s Phase 1 Investor newsletter — you just know that if you charge $5,000 for a subscription, and use one of the world’s largest investor mailing lists to tease a tiny stock in order [...]
Small Speculative Buy [Jan 24 update: and Sell]This is paid content, to view it, log in or register as an irregular.
I generally don’t like to write about super-heavily-hyped microcap stocks for the whole Gumshoe readership, because we’re almost guaranteed to cause a spike in the price for that stock. So when I saw the latest teaser for the Phase 1 folks over at Stansberry, and those teasers always cause a huge flood of emails to [...]
We have a charming little tradition here at Stock Gumshoe of picking out the stinkiest stock to have been teased over the past year, and calling it our “Turkey of the Year” come Thanksgiving time. It’s not particularly fair — certainly not to turkeys everywhere, and probably not to the newsletter folks who use breathless, [...]
I suppose I should expect this by now — whenever Frank Curzio and the gang put out a teaser for Phase 1 Investor, which is the big-money newsletter from Stansberry & Associates ($5,000/year, though almost always “on sale” at $3,000 when they’re running promos), my inbox gushes like Spindletop. Didn’t matter if it was a [...]
Here’s the lead-in to the latest ad for the Global Resource Alert “I’m Peter Krauth and I’d like to tell you a story about a “private vault”… “A ‘vault’ that contains nearly one million ounces of 99.9% pure gold bars ready for market, ready to sell for nearly $1.4 billion at today’s spot price. “This [...]
Phase 1′s “Next Royal Gold” … Hello, old friend!This is paid content, to view it, log in or register as an irregular.
You can always count on a good story from a Phase 1 teaser — Phase 1 is the fancy top-of-the-line upgrade newsletter from Stansberry & Associates ($5,000/year, though it’s usually “on sale” for $3,000 when they’re promoting it as they are now), currently edited by Frank Curzio, and it has historically focused on lots of [...]
I certainly don’t mean to impugn those without sight or hearing, but if you can read or listen, and have ever given your email address to any kind of financial website, chances are pretty good that you’ve been pitched this week about the “Chi-Tab” by Frank Curzio for his pricey Phase 1 newsletter at Stansberry [...]
Those who’ve been with the Gumshoe for a while know that it’s tough to top Stansberry’s Phase 1 Investor for marketing that uses over-the-top hyperbole about tiny biotech and mining stocks, and creative names that obscure the truth behind their investments — that doesn’t seem to have changed much with the new(ish) guy at the [...]
Well, as I noted in the Daily Update email on Friday, the Thermogenic Oil teaser from the Stansberry folks has garnered more interest from my readers than anything else in recent months — so at the very least, that copywriter deserves a raise. And I also said I’d try to take a closer look and [...]
“Gold Sands” — “A small, publicly traded micro-cap has stumbled onto the discovery of a lifetime”This is paid content, to view it, log in or register as an irregular.
“The Next ‘Trojan’ Could Pay You 4,750%”This is paid content, to view it, log in or register as an irregular.
I was going to hold off on writing about this teaser until Friday and cover it just for the Irregulars in the Friday File because it’s a tiny stock and I’ll very likely be influencing the price by writing about it for this larger group today — but I’ve gotten so many questions in just [...]
There’s a small stack of potential teasers just sitting and waiting for the attention of the Thinkolator, but your friendly neighborhood Gumshoe is but a humble servant to the masses of the assembled Gumshoe faithful … so when I start getting hundreds of questions about one specific teaser, that moves to the top of the [...]
A large number of readers have sent in copies of the latest tease for Matt Badiali’s gold stock picks — Matt is the editor of the S&A Resource Report, a pretty popular but inexpensive (and therefore large) oil and commodities newsletter, but this time he’s sharing his picks only with the subscribers of Phase 1 [...]
Late last week I wrote about a new teaser from the Phase 1 newsletter at Stansberry & Associates — as far as these things go it’s actually a relatively low-hype, fact-based teaser ad, since there’s a pretty big fundamental argument in favor of anyone who can profit from Iraq’s oil reserves (as well as lots [...]
This ad is getting a lot of attention from my readers, if my inbox is any indication — it’s for the Phase 1 Investor service from Stansberry & Associates, which is their expensive premium letter that has historically focused mostly on biotech stocks but is also used by them for any super-tiny stocks that would [...]
I don’t see this very often, but it looks like there’s a little battle brewing between Ian Cooper and Rob Fannon … or probably more precisely, between Stansberry & Associates and Angel Publishing. I don’t know if this has anything to do with it, but the two seem linked in several “sincerest form of flattery” [...]
Stansberry & Associates’ Phase 1 Investor newsletter is teasing us about shares of a drug company: “On March 30, FDA results we’ve waited 2 years to receive could make you $195,600, overnight” — and they quote Porter Stansberry as saying that “This is the kind of situation that can change your life… where a $10,000 stake can allow you to literally quit work, forever.” Sounds nice, eh?